Chun-yu Jin
Shanghai Jiao Tong University
7 Papers
1 Citations
Chun-yu Jin is an academic researcher from Shanghai Jiao Tong University. The author has contributed to research in topics: Antibody & Immune system. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity
Tailong Qu,Tingting Zhong,Xinghua Pang,Zhao-liang Huang,Chun-yu Jin,Zhongmin Maxwell Wang,Baiyong Li,Yuanyuan Xia +7 more
TL;DR: Ligufalimab (AK117) as discussed by the authors is a humanized IgG4 anti-CD47 antibody without hemagglutination effect, which is a promising therapeutic strategy for cancer treatment with unique safety features.
Abstract 5520: AK129, an anti-PD1/LAG-3 bi-specific antibody for cancer therapy
Zhao-liang Huang,Xinghua Pang,Tingting Zhong,Chun-yu Jin,N. Chen,Dennis Xia,Peng Zhang,Maxwell Zhongmin Wang,Michelle Xia,Baiyong Li +9 more
TL;DR: At the whole cell level, the enhancement effect of AK129 is stronger than the combination of penpulimab and relatlimab, as evidenced by significantly higher level of IL-2 and IFN-γ secretion from PBMCs.
2
Experimental measurements of turbulent boundary layer flow over a square-edged rib
TL;DR: In this paper, statistical quantities of the turbulent separated and reattaching flow were determined in terms of wall static pressure distri- bution, profiles of the streamwise velocity and its fluctuations, wall pressure fluctuation coefficient, and wall pressure spectra.
1
Abstract 5524: AK127, a novel monoclonal antibody (mAb) targeting T cell immunoreceptor (TIGIT)
Zhao-liang Huang,Xinghua Pang,Tingting Zhong,Chun-yu Jin,N. Chen,Dennis Xia,Peng Zhang,Maxwell Zhongmin Wang,Michelle Xia,Baiyong Li +9 more
TL;DR: The combination of AK127 and AK104 produced a significantly enhanced anti-tumor effect than either monotherapy, demonstrating the synergistic anti-Tumor activity of AK 127 combined with AK104.
Abstract 5526: AK131, an anti-PD1/CD73 bispecific antibody for cancer immune therapy
Zhao-liang Huang,Xinghua Pang,Tingting Zhong,Chun-yu Jin,N. Chen,Dennis Xia,Peng Zhang,Maxwell Zhongmin Wang,Michelle Xia,Baiyong Li +9 more
TL;DR: AK131 effectively blocked PD-1/PDL-1 interaction, promoted the activation of T cells and B cells, inhibited the CD73 enzymatic activity, and induced CD73 endocytosis in in-vivo activities.